Sotera Health Company Common Stock vs Vertex Pharmaceuticals Incorporated — how do they compare? Sotera Health Company Common Stock trades at $17.68 (market cap $5.20B), while Vertex Pharmaceuticals Incorporated trades at $503 (market cap $122.98B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 23.6× Sotera Health Company Common Stock's market cap, and Sotera Health Company Common Stock is more actively traded (1,647,777 versus 1,155,743). Which is the better fit depends on your goals — on Pluang, investors hold Sotera Health Company Common Stock for 0 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SHC | VRTX | |
|---|---|---|
Market Cap | $5.20B | $122.98B |
Volume | 1,647,777 | 1,155,743 |
Sector | Health | Health |
52-Week High | $19.57 | $557.96 |
52-Week Low | $13.13 | $407.90 |
Typical Hold Time | 0 Days | 120 Days |
Enterprise Value | $7.11B | $117.11B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Vertex Pharmaceuticals (VRTX) trades at $498.50, down 1.68% amid mixed technical signals. The stock shows strong fundamentals with $12B revenue, 35% net margins, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Technical indicators show bearish momentum with support at $496 and resistance at $512.
Outlook remains positive with 86% analyst buy ratings and $573.50 price target. Key risks include clinical trial outcomes and competitive pressures. The company's expanding pipeline and profitability provide upside potential, though near-term volatility may persist around key technical levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Sotera Health Company is a US provider of sterilization and lab testing services for the healthcare industry, operating through its Sterigenics, Nordion, and Nelson Labs businesses.
Read more on SHC →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →